Details for New Drug Application (NDA): 208694
✉ Email this page to a colleague
The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-eight suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
Summary for 208694
| Tradename: | ZERVIATE |
| Applicant: | Harrow Eye |
| Ingredient: | cetirizine hydrochloride |
| Patents: | 4 |
Pharmacology for NDA: 208694
| Mechanism of Action | Histamine H1 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 208694
Suppliers and Packaging for NDA: 208694
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694 | NDA | Harrow Eye, LLC | 82667-015 | 82667-015-24 | 1 POUCH in 1 CARTON (82667-015-24) / 30 VIAL, SINGLE-USE in 1 POUCH / 2.5 mL in 1 VIAL, SINGLE-USE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | EQ 0.24% BASE | ||||
| Approval Date: | May 30, 2017 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 15, 2030 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jan 9, 2033 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 15, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
